Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
NCT00002546
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy is more effective than combination chemotherapy in treating patients with cancer of the uterus. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to combination chemotherapy in treating patients with cancer of the... Read More
Gender:
FEMALE
Ages:
Between 21 years and 120 years
Trial Updated:
02/10/2016
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +64 locations
Conditions: Sarcoma
Register for Updates
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
NCT00847015
Completed
The purpose of this study is to find out if using the combination of standard chemotherapy (gemcitabine and cisplatin) plus this new targeted pill (sunitinib) can help shrink your tumor before you undergo surgery for your bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2016
Locations: Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Bladder Cancer, Urinary Bladder
Register for Updates
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
NCT00659269
Completed
Many types of chemotherapy may cause nerve damage as a side effect. This neurotoxicity can manifest as peripheral sensory neuropathy (characterized by numbness, tingling, or pain). The goal of this study is to determine the efficacy of the combination of vitamin B6 and B12 in preventing chemotherapy induced neuropathy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2016
Locations: University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico +4 locations
Conditions: Cancer
Register for Updates
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT01697072
Terminated
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/18/2016
Locations: Research Site, Tucson, Arizona +190 locations
Conditions: Gastric Cancer
Register for Updates
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
NCT00109954
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. In this case, chemotherapy is given through the artery (hepatic artery) that brings blood to the tumor. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumo... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/15/2016
Locations: Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Liver Cancer
Register for Updates
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
NCT01161498
Terminated
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2016
Locations: Investigative Clinical Research of Indiana, Indianapolis, Indiana +5 locations
Conditions: Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
NCT01093092
Terminated
This phase I trial studies the side effects and best dose of calcitriol when given with cisplatin and gemcitabine hydrochloride in treating patients with advanced solid tumors that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Calcitriol may stop the growth of tumor cells by blocking blood flow to the tumor. Calcitri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2016
Locations: Roswell Park Cancer Institute, Buffalo, New York +1 locations
Conditions: Adult Solid Neoplasm
Register for Updates
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
NCT00919061
Completed
The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and gallbladder cancers. We are looking to improve treatment results. We will attempt to do so by adding sorafenib (a type of monoclonal antibody) to your treatment plan. Sorafenib acts by attaching to blocking specific targets on cells. These targets may help the cancer cells gr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2016
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Register for Updates
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
NCT00737438
Completed
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments. We also will find out the effects, both good and/or bad, a drug called bevacizumab has on you and your tumor when given with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2016
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +4 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
SBRT + TACE for Primary Hepatocellular Carcinoma
NCT00746655
Withdrawn
The purpose of this study is to determine the feasibility and toxicity of combining SBRT and TACE for unresectable HCC and to evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2015
Locations: UPMC Presbyterian/Montifore, Pittsburgh, Pennsylvania +3 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
NCT00084838
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS)... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/18/2015
Locations: Stanford Cancer Center, Stanford, California +11 locations
Conditions: Central Nervous System Tumor, Pediatric
Register for Updates
Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
NCT00590031
Completed
Patients with surgically resectable T1N1M0 or T2-4N any M0 esophageal carcinoma will receive six weeks of induction chemotherapy with weekly irinotecan and cisplatin given weeks 1, 2, 4 and 5. Patients will then receive weekly irinotecan, cisplatin, and concurrent radiotherapy with chemotherapy given once weekly, weeks 8,9,11 and 12 during the six weeks of radiotherapy. Patients will be referred for surgery 4-8 weeks after completion of chemoradiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Esophageal Carcinoma
Register for Updates